Cover Image
市場調查報告書

人類免疫力缺乏病毒 (HIV)-1治療藥市場分析:各類藥物 (核苷酸類似體逆轉錄抑制劑 (NRTI),非NRTI,侵入、融合抑制劑,蛋白分解酵素抑制劑,整合酶抑製劑,共受體拮抗劑)的市場區隔預測

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), Segment Forecasts, 2014-2025

出版商 Grand View Research, Inc. 商品編碼 408923
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
人類免疫力缺乏病毒 (HIV)-1治療藥市場分析:各類藥物 (核苷酸類似體逆轉錄抑制劑 (NRTI),非NRTI,侵入、融合抑制劑,蛋白分解酵素抑制劑,整合酶抑製劑,共受體拮抗劑)的市場區隔預測 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), Segment Forecasts, 2014-2025
出版日期: 2016年10月24日 內容資訊: 英文 75 Pages
簡介

本報告提供全球人類免疫力缺乏病毒 (HIV)-1治療藥市場相關調查,市場趨勢,各類藥物,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 調查方法及調查範圍

第2章 摘要整理與市場概要

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
  • 市場規模與成長預測
    • 促進要素分析
    • 阻礙要素分析
  • SWOT分析:各要因
  • 產業分析:波特

第4章 各類藥物預測、趨勢分析

  • 各類藥物趨勢分析
  • 核苷酸類似體逆轉錄抑制劑 (NRTI)
  • 非核苷酸類似體逆轉錄抑制劑
  • 侵入、融合抑制劑
  • 蛋白分解酵素抑制劑
  • 整合酶抑製劑  
  • 聯合受體拮抗劑

第5章 各地區預測、趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第6章 競爭環境

  • 策略架構
  • 競爭簡介
目錄
Product Code: GVR-1-68038-210-5

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Further Key Findings from the Study Suggest:

  • NRTIs were the largest class of drugs available in the market in 2015 accounting for over 40% of total drugs available in this vertical
  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • In 2015, North America held the largest market share in 2015 with a share of over 35%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Table of Content

Chapter 1 Methodology & Scope

  • 1.1 Research Methodology
  • 1.2 Research Scope & Assumptions
  • 1.3 List of Data Sources

Chapter 2 Executive Summary and Market Snapshot

  • 2.1 Market Snapshot

Chapter 3 HIV-1 Therapeutics Market Variables, Trends& Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market size and growth prospects
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Market Restraint Analysis
      • 3. Penetration & growth prospect mapping
  • 3.4 HIV-1 Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.5 Industry Analysis - Porter's

Chapter 4 HIV-1 TherapeuticsMarket Drug Class Estimates & Trend Analysis

  • 4.1 HIV-1 Therapeutics market: Drug Class movement analysis
  • 4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 4.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
  • 4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 4.3.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)market estimates and forecasts, by drug class, 2014 - 2025 USD Million
  • 4.4 Entry and Fusion Inhibitors
    • 4.4.1 Entry and fusion Inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
  • 4.5 Protease Inhibitors (PIs)
    • 4.5.1 Protease Inhibitors (PIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
  • 4.6 Integrase Inhibitors
    • 4.6.1 Integrase inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
  • 4.7 Coreceptor Antagonists
    • 4.7.1 Coreceptor antagonists market estimates and forecasts, by drug class, 2014 - 2025 USD Million

Chapter 5 HIV-1 Therapeutics Market Regional Estimates & Trend Analysis

  • 5.1 HIV-1 Therapeutics market share by region, 2014& 2025
  • 5.2 North America
    • 5.2.1 North America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
      • 5.2.1.1 U.S.
      • 5.2.1.2 Canada
  • 5.3 Europe
    • 5.3.1 Europe market estimates and forecasts, by drug class, 2014 - 2025 USD Million
      • 5.3.1.1 UK
      • 5.3.1.2 Germany
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific market estimates and forecasts, by drug class, 2014 - 2025 USD Million
      • 5.4.1.1 Japan
      • 5.4.1.2 China
      • 5.4.1.3 India
  • 5.5 Latin America
    • 5.5.1 Latin America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
      • 5.5.1.1 Mexico
      • 5.5.1.2 Brazil
  • 5.6 MEA
    • 5.6.1 MEA market estimates and forecasts, by drug class, 2014 - 2025 USD Million
      • 5.6.1.1 South Africa

Chapter 6 Competitive Landscape

  • 6.1 Strategy framework
  • 6.2 Company Profiles
    • 6.2.1 AbbVie, Inc.
      • 6.2.1.1 Company Overview
      • 6.2.1.2 Financial Performance
      • 6.2.1.3 Product Benchmarking
      • 6.2.1.4 Strategic Initiatives
    • 6.2.2 Boehringer Ingelheim GmbH
      • 6.2.2.1 Company Overview
      • 6.2.2.2 Financial Performance
      • 6.2.2.3 Product Benchmarking
      • 6.2.2.4 Strategic Initiatives
    • 6.2.3 Bristol-Myers Squibb Company
      • 6.2.3.1 Company Overview
      • 6.2.3.2 Financial Performance
      • 6.2.3.3 Product Benchmarking
      • 6.2.3.4 Strategic Initiatives
    • 6.2.4 Cipla, Inc.
      • 6.2.4.1 Company Overview
      • 6.2.4.2 Financial Performance
      • 6.2.4.3 Product Benchmarking
      • 6.2.4.4 Strategic Initiatives
    • 6.2.5 Genentech, Inc.
      • 6.2.5.1 Company Overview
      • 6.2.5.2 Financial Performance
      • 6.2.5.3 Product Benchmarking
      • 6.2.5.4 Strategic Initiatives
    • 6.2.6 Gilead Sciences, Inc.
      • 6.2.6.1 Company Overview
      • 6.2.6.2 Financial Performance
      • 6.2.6.3 Product Benchmarking
      • 6.2.6.4 Strategic Initiatives
    • 6.2.7 Merck & Co., Inc.
      • 6.2.7.1 Company Overview
      • 6.2.7.2 Financial Performance
      • 6.2.7.3 Product Benchmarking
      • 6.2.7.4 Strategic Initiatives
    • 6.2.8 ViiV Healthcare
      • 6.2.8.1 Company Overview
      • 6.2.8.2 Financial Performance
      • 6.2.8.3 Product Benchmarking
      • 6.2.8.4 Strategic Initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 3 U.S. HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 4 Canada HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 5 Europe HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 6 UK HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 7 Germany HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 8 Asia Pacific HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 9 Japan HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 10 China HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 11 India HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 12 Latin America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 13 Mexico HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 14 Brazil HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 15 MEA HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 16 South Africa HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 HIV-1 Therapeutics: Market Segmentation
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 HIV-1 TherapeuticsPorter's analysis
  • FIG. 9 HIV-1 Therapeutics market Drug Classes outlook key takeaways
  • FIG. 10 HIV-1 Therapeutics market: Drug Classes movement analysis
  • FIG. 11 Globa lNRTIs market, 2014 - 2025 (USD Million)
  • FIG. 12 Global NNRTIs market, 2014 - 2025 (USD Million)
  • FIG. 13 Global Entry and Fusion Inhibitors market, 2014 - 2025 (USD Million)
  • FIG. 14 Global Protease Inhibitors (PIs) market, 2014 - 2025 (USD Million)
  • FIG. 15 Global Integrase Inhibitors market, 2014 - 2025 (USD Million)
  • FIG. 16 Global Coreceptor Antagonists market, 2014 - 2025 (USD Million)
  • FIG. 17 Regional market place: Key takeaways
  • FIG. 18 Regional outlook, 2015 & 2026
  • FIG. 19 Strategy framework
  • FIG. 20 Participant categorization
Back to Top